[Form 4] PMV Pharmaceuticals, Inc Insider Trading Activity

Rhea-AI Filing Summary

PMV Pharmaceuticals, Inc. (PMVP) filed a Form 4 disclosing that General Counsel & COO Robert Ticktin sold 23,151 common shares on 1 July 2025 at an average price of $1.0648 per share.

The filing states the shares were withheld for tax obligations arising from the vesting of restricted stock units (RSUs). Following the transaction, Ticktin retains 98,695 shares of PMVP, which include 15,528 shares purchased under the company’s Employee Stock Purchase Plan on 15 May 2025. No derivative security transactions were reported.

The sale represents a disposition of approximately 19% of his prior directly held shares; however, because the purpose is tax-related rather than discretionary, the market signal is typically viewed as neutral.

Positive

• Officer retains 98,695 shares, indicating continued equity exposure and alignment with shareholder interests.
• Sale was for tax-withholding tied to RSU vesting, suggesting no discretionary liquidation.

Negative

• Insider share sale—even if tax-related—can be perceived negatively and constituted about 19% of the officer’s direct holdings.
• Low average sale price of $1.0648 underscores ongoing share-price weakness, which may concern investors.

Insights

Securities Analyst

TL;DR: Routine tax-withholding sale; limited market impact.

The Form 4 shows PMVP’s COO disposing of 23,151 shares at $1.06 to settle RSU taxes, leaving nearly 99k shares outstanding. Such automatic sales are common and usually carry minimal informational content regarding future operating performance or insider sentiment. The retained stake remains material and includes a recent ESPP purchase, suggesting continued alignment with shareholders. Given PMVP’s low share price, the dollar value (~$25k) is immaterial to corporate valuation. Overall, I classify the filing as neutral to share price action.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ticktin Robert

(Last) (First) (Middle)

C/O PMV PHARMACEUTICALS, INC.

400 ALEXANDER PARK DRIVE, SUITE 301

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PMV Pharmaceuticals, Inc. [ PMVP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel & COO

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2025		S		23,151(1)	D	$1.0648	98,695(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.

2. Includes 15,528 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2025.

	/s/ Robert Ticktin	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many PMVP shares did the COO sell on July 1, 2025?

23,151 common shares were sold as reported in the Form 4.

What was the average sale price for the PMVP shares?

The reported average sale price was $1.0648 per share.

Why did the insider sell PMVP stock?

The shares were sold to satisfy tax obligations triggered by the vesting of restricted stock units (RSUs).

How many PMVP shares does the COO still own after the transaction?

After the sale, the officer beneficially owns 98,695 shares.

Does the filing report any derivative transactions?

No, no derivative securities were acquired or disposed of in this Form 4.

When were additional shares acquired under the ESPP?

15,528 shares were acquired through the Employee Stock Purchase Plan on May 15, 2025.